In a Washington Post opinion piece, former Trump FDA chief Dr. Scott Gottlieb argues the “CBD craze is getting out of hand. The FDA needs to act.”

  • Gottlieb, a relative CBD skeptic, says “The FDA can fulfill its public-health obligations and meet the political demand for these goods: It can approve the sale of some CBD products immediately, while effecting a framework for their safe and proper regulation and a pathway for an enforceable market for these goods.
  • He says the risks of CBD are, “It can cause damage to the liver at high doses, and it may have a cumulative effect. If you eat CBD in your breakfast, lunch and dinner, you could get a toxic dose. Currently marketed products might also have undeclared ingredients and impurities,” including THC.

Meanwhile, a venture between pharma giants Pfizer and GlaxoSmithKline is investigating CBD.

  • “The science is young in the space, but we realize it’s something consumers are using in their repertoire, so we are looking into it,” the venture’s CEO said.

Quick Hit

  1. The DEA is under pressure to explain why no federal research permits to grow MED have been granted since 2016.